NCT05474430 Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
| NCT ID | NCT05474430 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Philip Polgreen |
| Condition | Carrier State |
| Study Type | OBSERVATIONAL |
| Enrollment | 160 participants |
| Start Date | 2021-12-20 |
| Primary Completion | 2026-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 160 participants in total. It began in 2021-12-20 with a primary completion date of 2026-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays. An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19. The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Eligibility Criteria
CF Carrier Inclusion Criteria: * Previously tested and shown to be a CF carrier * English-speaking Control Group Inclusion Criteria: * Previously tested and shown to not be a CF carrier or CF patient * English-speaking Exclusion Criteria: * Currently sick with a respiratory infection * Prisoner Status * Unable to provide own written, informed consent
Contact & Investigator
Philip M Polgreen, MD
PRINCIPAL INVESTIGATOR
University of Iowa
Frequently Asked Questions
Who can join the NCT05474430 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Carrier State. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05474430 currently recruiting?
Yes, NCT05474430 is actively recruiting participants. Contact the research team at philip-polgreen@uiowa.edu for enrollment information.
Where is the NCT05474430 trial being conducted?
This trial is being conducted at Iowa City, United States.
Who is sponsoring the NCT05474430 clinical trial?
NCT05474430 is sponsored by Philip Polgreen. The principal investigator is Philip M Polgreen, MD at University of Iowa. The trial plans to enroll 160 participants.